|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 3, July-September 2021
SWITCHING TO GUSELKUMAB IN MODERATE-TO-SEVERE PSORIASIS: ROLE OF PATIENT-REPORTED OUTCOMES AND HOSPITAL PHARMACISTS
MERCADAL ORFILA GABRIEL, ESCRIVÁ SANCHO EUGENIA, BLASCO MASCARÓ IGNACIO, LIÑANA GRANELL CARLA, ROMERO DEL BARCO ROCÍO
Objective: The study objective was to assess the value of patient-reported outcomes
(PRO) in guiding the switching of biological agents in patients with moderate-to-severe
psoriasis attending hospital pharmacy clinics.
Method: At the suggestion of hospital pharmacists, 45 patients completed the Psoriasis Symptoms and Signs Diary with seven-day recall (PSSD_7D). Those with a PSSD_7D score of ≥20 were referred to the dermatology service for switching to guselkumab. The PSSD_7D score was reassessed after one, six and 12 months of guselkumab therapy.
Results: Fourteen patients had a PSSD_7D score of ≥20. All were accepted for switching to guselkumab at standard doses. An improvement in the mean PSSD_7D
score was already clear within the first month of guselkumab therapy. After 12 months,
the score was 83.4% lower than at baseline.
Conclusions: A PRO instrument could be useful in clinical practice to guide biological therapy in patients with psoriasis.
DRUG SWITCHING – GUSELKUMAB – PATIENT-REPORTED OUTCOMES – PSORIASIS